title: Endocrine abnormalities in patients with endstage renal failure.
abstract: Data presented in this study suggest existence of hyperendorphinism in uraemic patients. This hyperendorphinism may be regarded both as a primary beneficial compensatory mechanism counteracting disturbances of the internal environment, while causing secondary harmful side effects, which contribute to the uraemic state. Erythropoietin treatment of uraemic, haemodialyzed patients is followed by marked endocrine alterations (suppression of plasma levels of STH, ACTH, prolactin, glucagon, aldosterone, cortisol and plasma renin activity, elevation of plasma insulin and atrial natriuretic levels, lack of influence on plasma PTH, CT and AVP). It remains to be clarified whether the erythropoietin induced endocrine alterations are due to correction of the existing anaemia or reflect a specific effect of this hormone.
authors.affiliation: Department of Nephrology Silesian School of Medicine, Katowice.
authors.forename: F
authors.initials: F
authors.lastname: Kokot
authors.forename: A
authors.initials: A
authors.lastname: Wiecek
authors.forename: W
authors.initials: W
authors.lastname: Grzeszczak
authors.forename: J
authors.initials: J
authors.lastname: Klepacka
authors.forename: M
authors.initials: M
authors.lastname: Klin
authors.forename: M
authors.initials: M
authors.lastname: Lao
mesh_terms: D004700:Endocrine System Diseases / Q000188:drug therapy / Q000209:etiology*; D004921:Erythropoietin / Q000627:therapeutic use; D006728:Hormones / Q000097:blood; D006801:Humans; D007676:Kidney Failure, Chronic / Q000150:complications / Q000188:drug therapy / Q000503:physiopathology*; D011957:Receptors, Opioid / Q000502:physiology*; D006435:Renal Dialysis
chemical_list: D006728:Hormones; D011957:Receptors, Opioid; D004921:Erythropoietin